To The Moon

$Johnson & Johnson(JNJ)$

Johnson & Johnson is a global healthcare company with operations spanning pharmaceuticals, medical devices, and consumer health products. The company develops prescription medications for conditions like cancer and autoimmune diseases, manufactures surgical equipment and devices such as joint replacements and contact lenses, and sells widely recognized consumer brands like Tylenol, Band-Aid, Neutrogena, and Listerine.

Earning Overview

In their latest quarterly report, oncology contributed significantly to revenue, totaling around $5.4 billion. Other areas, such as infectious diseases and neurosciences, also played a role. Despite these revenue streams, the company’s overall performance has been underwhelming. Its stock declined 11% over the past year and has risen only 38% over the last decade, substantially under performing the S&P 500. Currently trading near its 52-week low, Johnson & Johnson remains attractive to some analysts, with Seeking Alpha and Wall Street giving it a “double buy” recommendation, supported by an appealing starting dividend yield of 3.44%.

Fundamental Analysis

Johnson & Johnson reported a sales increase of 5.2% year-over-year in their latest quarter, though earnings per share (EPS) and adjusted EPS declined. While they raised their sales outlook, the company has lagged behind the S&P 500 for an extended period. Out of the next four quarters, only Q3 2025 is expected to show growth. On the positive side, the company has outperformed analyst targets for four consecutive quarters and maintains a forward P/E ratio with projected EPS growth of 10.64% in 2025.

Known as a "Dividend King," Johnson & Johnson boasts a strong dividend safety score of 99, making a dividend cut highly unlikely. However, the dividend increase of around 4% last year was modest and in line with inflation. Historically, the company has increased dividends even during economic downturns, such as the 2007-2009 recession, and delivered above-average performance compared to the S&P 500 during that period.

Sales growth has been inconsistent but is projected to meet inflationary benchmarks, with 2023 and 2024 showing positive momentum. While Johnson & Johnson’s growth expectations differ from high-growth tech companies like Microsoft or Nvidia, the company’s stable performance reflects its mature industry position.

Revenue growth has been modest, largely aligning with inflation. However, net income has shown inconsistency, diverging from revenue trends. In 2023, net income stood at $35 billion, but it is projected to drop by more than half based on trailing 12-month estimates.

Balance Sheet: The company maintains a healthy financial position. Cash has decreased over the years, from $33 billion in 2014 to $20 billion in the latest quarter. Conversely, total debt has risen from $19 billion in 2014 to $36 billion. Despite this, the net debt-to-EBITDA ratio remains low at 0.51, indicating no significant concerns regarding dividend safety or overall financial health.

ROIC and Operating Margin

The return on invested capital (ROIC) consistently exceeds the 10% benchmark, demonstrating effective capital allocation, with a trailing 12-month ROIC of 21%. Operating margins remain steady, well above the desired 12%, showing operational efficiency and consistency year-over-year.

Balance Sheet and Debt Metrics

The company’s net debt-to-EBITDA ratio is an impressive 0.51, indicating it could pay off all debt in under a year using available cash flows. This aligns with its strong balance sheet and high dividend safety score.

Guidance

Johnson & Johnson has returned value to shareholders through share buybacks, though the frequency and scale of repurchases have varied over the years. The recent significant reduction in shares outstanding suggests management sees the current valuation as an opportunity, reflecting their confidence in the company being undervalued.

Free Cash Flow

The free cash flow payout ratio—a metric less prone to manipulation than earnings—currently sits at 61%. This aligns with the company’s ability to maintain dividend increases above inflation. While recent years have seen some challenges, free cash flow is expected to jump significantly in the next 12 months to $819 per share.

Johnson & Johnson generates consistent operational cash flow, increasing from $19 billion in 2014 to $25 billion in the trailing 12 months. This reflects the company’s strong cash-generating capabilities.

Technical Analysis

Support Levels: $140: Strong psychological and technical support. The stock has tested this level multiple times in recent months.$135: Secondary support if $140 fails, a critical level from prior years.

Resistance Levels: $150: A key near-term resistance, representing the stock's first upward barrier.$160: A significant intermediate resistance level, aligned with prior peaks.$175–$179: The upper boundary of its 52-week range, acting as major resistance.

Risks and Challenges

Legal Challenges

In 2024, Johnson & Johnson continued facing legal challenges over claims that its talc-based products caused cancer. To address these lawsuits, the company proposed a settlement of approximately $8 billion, payable over 25 years, securing support from about 83% of claimants. However, this legal uncertainty has weighed heavily on investor sentiment, reflected in the company’s struggling stock performance through 2024 and into early 2025.

Operational Challenges

The MedTech segment encountered headwinds due to economic slowdowns in Asia and a physician strike in Korea, which impacted sales growth. Despite these setbacks, the division achieved 6.4% operational growth in Q3 FY2024. Additionally, the acquisition of TheWave, a private medical technology company, led to a special charge affecting financials and the company’s full-year profit forecast. These factors have further influenced investor perceptions.

Performance Relative to Peers

Over the past year, Johnson & Johnson underperformed its pharma peers with a -8% return, while the broader pharma sector also struggled. Over 5 and 10 years, J&J’s total returns, including dividends, were 15% and 82%, respectively—significantly lagging the S&P 500.

Valuation

As mentioned, Johnson & Johnson is a "Dividend King," boasting over 50 consecutive years of dividend increases without any reductions. Examining the company through a valuation lens reveals several signals of potential undervaluation.

The company earns a D+ for valuation, primarily due to its forward-looking metrics. However, its forward P/E ratio is 28% lower than the healthcare sector average, signaling a potential buying opportunity for value investors.

Growth: With an F rating for growth, revenue increased by just 5% year-over-year, compared to the sector median of 7.6%. Forward revenue growth is expected to decline by 1%, significantly underperforming the sector's expected 7.6%. However, EPS is projected to grow at 6% annually over the next 3–5 years, below the sector’s 10.64%.

Profitability: The company shines here, earning an A+ for profitability. Johnson & Johnson’s operating margin of 17% and cash flow from operations of $25 billion far outperform the sector, which reported negative metrics in these areas.

Intrinsic Value Signals

Using the 5-year average P/E ratio as a reference, the company’s current price falls below the lower end of the expected fair value range, as indicated by the blue valuation tunnel. This suggests significant undervaluation. However, we’ll integrate this finding into a comprehensive valuation process rather than relying solely on one model.

The forward P/E ratio of 14 is below the 5-year average and the broader healthcare sector’s average of 15.3. This discount relative to its peers strengthens the argument that Johnson & Johnson is undervalued.

Using three valuation methods—multiples, dividend discount, and discounted cash flow (DCF)—the average intrinsic value is estimated at $175 per share.

Multiples Valuation: Suggests undervaluation based on J&J’s EPS and sector PE comparison.

Dividend Discount Model: Projects steady dividend growth, conservatively estimated at 5.5% annually.

DCF Analysis: Using a 6% free cash flow growth rate, the present value of future cash flows and terminal value indicate undervaluation.

The $175 intrinsic value reflects a 22% upside from the current price of ~$140. Applying a 10%–20% margin of safety, the buy range falls between $157 and $140.

Wall Street analysts also give Johnson & Johnson a buy rating with a 1-year price target of $174, offering a similar upside. Combined with a dividend yield higher than its 5-year average—currently the highest in that timeframe—this makes J&J an attractive dividend play.

Market sentiment

Despite its challenges, Johnson & Johnson remains a potentially undervalued opportunity for investors. With a history of dividend stability and resilience during past economic crises, the company could appeal to long-term investors seeking a reliable income source. However, concerns over legal uncertainties, operational hurdles, and slower stock growth may temper enthusiasm.

Insider and Institutional Activity

Johnson & Johnson’s insider ownership sits at approximately 1.16%, with $10 million worth of insider sales recorded over the past year compared to just $147,000 in insider purchases. In the latest quarter of 2025, there was no insider activity, while Q4 2024 showed minor insider buying, signaling recent bullish sentiment. The most notable recent insider purchase occurred on December 12th, totaling $147,000—while small, it could be interpreted as a positive signal.

Institutional ownership is around 70%, with $16 billion in sales and $19.2 billion in purchases over the last year. Institutions were net buyers in both Q3 and Q4 of 2024, further suggesting confidence in the stock. However, as always, investors should perform their own due diligence rather than solely relying on insider or institutional actions.

Conclusion

Johnson & Johnson’s strong cash flow generation, high dividend safety, and signs of undervaluation across multiple metrics position it as a solid long-term investment. While growth expectations are modest, its consistent financial performance and management confidence through buybacks suggest this could be an attractive opportunity for dividend-focused investors.

While Johnson & Johnson demonstrates strong profitability, robust cash flow, and potential undervaluation, investors should consider the broader context, including ongoing legal challenges and underperformance relative to the market. As always, thorough due diligence is essential to ensure it aligns with your investment strategy and goals.

@Daily_Discussion @TigerPM @TigerObserver @Tiger_comments @TigerClub